The FDA approved Novartis’ combination therapy for anaplastic thyroid cancer that cannot be removed surgically.

The therapy uses a combination of the company’s Mekinist and Tafinlar. It is the first FDA-approved treatment for patients with such a form of cancer and the third for patients with this specific gene mutation.

The combination is also approved for use in a type of lung cancer with the BRAF V600E gene.